Current landscape and future directions for systemic treatments of hepatocellular carcinoma  

作　　者：Leonardo G.Fonseca Flair J.Carrilho 

机构地区：[1]Clinical Oncology,Instituto do Cancer do Estado de São Paulo,Hospital das Clínicas,University of São Paulo School of Medicine,São Paulo 05403-000,Brazil [2]Division of Clinical Gastroenterology and Hepatology,Hospital das Clínicas,Department of Gastroenterology,University of São Paulo School of Medicine,São Paulo 05403-000,Brazil

出　　处：《Hepatoma Research》2023年第1期1-5,共5页肝癌研究(英文版)

摘　　要：Systemic treatment is the optimal approach for patients with advanced or intermediate-stage hepatocellular carcinoma(HCC)with contraindications or refractoriness to locoregional treatments[1].The aim of systemic treatment is to prolong survival and delay clinical deterioration.Until 2008,no systemic therapy provided meaningful clinical benefit.In the past,studies that evaluated the role of conventional chemotherapy,mainly doxorubicin or combinations of platinum agents,resulted in significant toxicities,without a clear demonstration of efficacy[2].

关 键 词：HEPATOCELLULAR TREATMENT CLINICAL 

分 类 号：R73[医药卫生—肿瘤]